Clinical Significance and Biological Basis of HIV Drug Resistance

  • Jorge L. Martinez-Cajas
  • Marco Petrella
  • Mark A. Wainberg
Part of the Emerging Infectious Diseases of the 21st Century book series (EIDC)


Antimicrob Agent Drug Resistance Mutation CCR5 Antagonist Nonnucleoside Inhibitor Inhibitory Quotient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. DDHS Panel on Antiretoviral Guidelines for Adult & Adolescents, (2006), Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Office of AIDS Research Advisory Council. AIDS Info/US Department of Health and Human Services.Google Scholar
  2. Ait-Khaled, M., Rakik, A., Griffin, P., Stone, C., Richards, N., Thomas, D., Falloon, J. and Tisdale, M., (2003), HIV-1 reverse transcriptase and protease resistance mutations selected during 16–72 weeks of therapy in isolates from antiretroviral therapy-experienced patients receiving abacavir/efavirenz/amprenavir in the CNA2007 study. Antivir Ther, 8, 111–120.PubMedGoogle Scholar
  3. Ait-Khaled, M., Stone, C., Amphlett, G., Clotet, B., Staszewski, S., Katlama, C. and Tisdale, M., (2002), M184V is associated with a low incidence of thymidine analogue mutations and low phenotypic resistance to zidovudine and stavudine. AIDS, 16, 1686–1689.PubMedCrossRefGoogle Scholar
  4. Alexander, C.S., Montessori, V., Wynhoven, B., Dong, W., Chan, K., O’Shaughnessy, M.V., Mo, T., Piaseczny, M., Montaner, J.S. and Harrigan, P.R., (2002), Prevalence and response to antiretroviral therapy of non-B subtypes of HIV in antiretroviral-naive individuals in British Columbia. Antivir Ther, 7, 31–35.PubMedGoogle Scholar
  5. Allen, T.M. and Altfeld, M., (2003), HIV-1 superinfection. J Allergy Clin Immunol, 112, 829.PubMedCrossRefGoogle Scholar
  6. Altfeld, M., Allen, T.M., Yu, X.G., Johnston, M.N., Agrawal, D., Korber, B.T., Montefiori, D.C., O’Connor, D.H., Davis, B.T., Lee, P.K., Maier, E.L., Harlow, J., Goulder, P.J., Brander, C., Rosenberg, E.S. and Walker, B.D., (2002), HIV-1 superinfection despite broad CD8+ T-cell responses containing replication of the primary virus. Nature, 420, 434–439.PubMedCrossRefGoogle Scholar
  7. Ammaranond, P., Cunningham, P., Oelrichs, R., Suzuki, K., Harris, C., Leas, L., Grulich, A., Cooper, D.A. and Kelleher, A.D., (2003), No increase in protease resistance and a decrease in reverse transcriptase resistance mutations in primary HIV-1 infection: 1992–2001. AIDS, 17, 264–267.PubMedCrossRefGoogle Scholar
  8. Apetrei, C., Descamps, D., Collin, G., Loussert-Ajaka, I., Damond, F., Duca, M., Simon, F. and Brun-Vezinet, F., (1998), Human immunodeficiency virus type 1 subtype F reverse transcriptase sequence and drug susceptibility. J Virol, 72, 3534–3538.PubMedGoogle Scholar
  9. Bacheler, L., Jeffrey, S., Hanna, G., D’Aquila, R., Wallace, L., Logue, K., Cordova, B., Hertogs, K., Larder, B., Buckery, R., Baker, D., Gallagher, K., Scarnati, H., Tritch, R. and Rizzo, C., (2001), Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy. J Virol, 75, 4999–5008.PubMedCrossRefGoogle Scholar
  10. Badri, S.M., Adeyemi, O.M., Max, B.E., Zagorski, B.M. and Barker, D.E., (2003), How does expert advice impact genotypic resistance testing in clinical practice? Clin Infect Dis, 37, 708–713.PubMedCrossRefGoogle Scholar
  11. Balotta, C., Berlusconi, A., Pan, A., Violin, M., Riva, C., Colombo, M.C., Gori, A., Papagno, L., Corvasce, S., Mazzucchelli, R., Facchi, G., Velleca, R., Saporetti, G., Galli, M., Rusconi, S. and Moroni, M., (2000), Prevalence of transmitted nucleoside analogue-resistant HIV-1 strains and pre-existing mutations in pol reverse transcriptase and protease region: outcome after treatment in recently infected individuals. Antivir Ther, 5, 7–14.PubMedGoogle Scholar
  12. Balzarini, J., Karlsson, A., Perez-Perez, M.J., Camarasa, M.J., Tarpley, W.G. and De Clercq, E., (1993), Treatment of human immunodeficiency virus type 1 (HIV-1)-infected cells with combinations of HIV-1-specific inhibitors results in a different resistance pattern than does treatment with single-drug therapy. J Virol, 67, 5353–5359.PubMedGoogle Scholar
  13. Barbour, J.D., Hecht, F.M., Wrin, T., Liegler, T.J., Ramstead, C.A., Busch, M.P., Segal, M.R., Petropoulos, C.J. and Grant, R.M., (2004), Persistence of primary drug resistance among recently HIV-1 infected adults. AIDS, 18, 1683–1689.PubMedCrossRefGoogle Scholar
  14. Baxter, J.D., Mayers, D.L., Wentworth, D.N., Neaton, J.D., Hoover, M.L., Winters, M.A., Mannheimer, S.B., Thompson, M.A., Abrams, D.I., Brizz, B.J., Ioannidis, J.P. and Merigan, T.C., (2000), A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS. AIDS, 14, F83–F93.PubMedCrossRefGoogle Scholar
  15. Becker-Pergola, G., Kataaha, P., Johnston-Dow, L., Fung, S., Jackson, J.B. and Eshleman, S.H., (2000), Analysis of HIV type 1 protease and reverse transcriptase in antiretroviral drug-naive Ugandan adults. AIDS Res Hum Retroviruses, 16, 807–813.PubMedCrossRefGoogle Scholar
  16. Bennett, D., McCormick, L., Kline, R., Wheeler, W., Hemmen, M., Smith, A., Zaidi, I., Donolero, T. and the HIV Drug Resistant AVRDRP/VARHS Surveillance Group, (2005), US surveillance of HIV drug resistance at diagnosis using HIV diagnostic sera. 12th Conference on Retroviruses and Opportunistic Infections. Feb 22–25. Boston, MA. Abstract 674.Google Scholar
  17. Birk, M. and Sonnerborg, A., (1998), Variations in HIV-1 pol gene associated with reduced sensitivity to antiretroviral drugs in treatment-naive patients. AIDS, 12, 2369–2375.PubMedCrossRefGoogle Scholar
  18. Boden, D., Hurley, A., Zhang, L., Cao, Y., Guo, Y., Jones, E., Tsay, J., Ip, J., Farthing, C., Limoli, K., Parkin, N. and Markowitz, M., (1999), HIV-1 drug resistance in newly infected individuals. JAMA, 282, 1135–1141.PubMedCrossRefGoogle Scholar
  19. Boden, D. and Markowitz, M., (1998), Resistance to human immunodeficiency virus type 1 protease inhibitors. Antimicrob Agents Chemother, 42, 2775–2783.PubMedGoogle Scholar
  20. Bossi, P., Peytavin, G., Ait-Mohand, H., Delaugerre, C., Ktorza, N., Paris, L., Bonmarchand, M., Cacace, R., David, D.J., Simon, A., Lamotte, C., Marcelin, A.G., Calvez, V., Bricaire, F., Costagliola, D. and Katlama, C., (2004), GENOPHAR: a randomized study of plasma drug measurements in association with genotypic resistance testing and expert advice to optimize therapy in patients failing antiretroviral therapy. HIV Med, 5, 352–359.PubMedCrossRefGoogle Scholar
  21. Boyer, P.L., Currens, M.J., McMahon, J.B., Boyd, M.R. and Hughes, S.H., (1993), Analysis of nonnucleoside drug-resistant variants of human immunodeficiency virus type 1 reverse transcriptase. J Virol, 67, 2412–2420.PubMedGoogle Scholar
  22. Brenner, B., Routy, J.P., Quan, Y., Moisi, D., Oliveira, M., Turner, D. and Wainberg, M.A., (2004), Persistence of multidrug-resistant HIV-1 in primary infection leading to superinfection. AIDS, 18, 1653–1660.PubMedCrossRefGoogle Scholar
  23. Brenner, B., Turner, D., Oliveira, M., Moisi, D., Detorio, M., Carobene, M., Marlink, R.G., Schapiro, J., Roger, M. and Wainberg, M.A., (2003), A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors. AIDS, 17, F1–F5.PubMedCrossRefGoogle Scholar
  24. Brenner, B.G., Routy, J.P., Petrella, M., Moisi, D., Oliveira, M., Detorio, M., Spira, B., Essabag, V., Conway, B., Lalonde, R., Sekaly, R.P. and Wainberg, M.A., (2002a), Persistence and fitness of multidrug-resistant human immunodeficiency virus type 1 acquired in primary infection. J Virol, 76, 1753–1761.CrossRefGoogle Scholar
  25. Brenner, B.G., Turner, D. and Wainberg, M.A., (2002b), HIV-1 drug resistance: can we overcome? Expert Opin Biol Ther, 2, 751–761.CrossRefGoogle Scholar
  26. Byrnes, V.W., Sardana, V.V., Schleif, W.A., Condra, J.H., Waterbury, J.A., Wolfgang, J.A., Long, W.J., Schneider, C.L., Schlabach, A.J., Wolanski, B.S., Graham, D.J., Gotlib, L., Rhodes, A., Titus, D.C., Roth, E., Blahy, OA., Quintero, J.C., Staszewki S. and Emini, E.A., (1993), Comprehensive mutant enzyme and viral variant assessment of human immunodeficiency virus type 1 reverse transcriptase resistance to nonnucleoside inhibitors. Antimicrob Agents Chemother, 37, 1576–1579.PubMedGoogle Scholar
  27. Cane, P., Chrystie, I., Dunn, D., Evans, B., Geretti, A.M., Green, H., Phillips, A., Pillay, D., Porter, K., Pozniak, A., Sabin, C., Smit, E., Weber, J. and Zuckerman, M., (2005), Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational study. BMJ, 331, 1368.PubMedCrossRefGoogle Scholar
  28. Casado, J.L., Moreno, A., Sabido, R., Marti-Belda, P., Antela, A., Dronda, F., Perez-Elias, M.J. and Moreno, S., (2003), Individualizing salvage regimens: the inhibitory quotient (Ctrough/IC50) as predictor of virological response. AIDS, 17, 262–264.PubMedCrossRefGoogle Scholar
  29. Castagna, A., Gianotti, N., Galli, L., Danise, A., Hasson, H., Boeri, E., Hoetelmans, R., Nauwelaers, D. and Lazzarin, A., (2004), The NIQ of lopinavir is predictive of a 48-week virological response in highly treatment-experienced HIV-1-infected subjects treated with a lopinavir/ritonavir-containing regimen. Antivir Ther, 9, 537–543.PubMedGoogle Scholar
  30. Chaix, M.L., Descamps, D., Harzic, M., Schneider, V., Deveau, C., Tamalet, C., Pellegrin, I., Izopet, J., Ruffault, A., Masquelier, B., Meyer, L., Rouzioux, C., Brun-Vezinet, F. and Costagliola, D., (2003), Stable prevalence of genotypic drug resistance mutations but increase in non-B virus among patients with primary HIV-1 infection in France. AIDS, 17, 2635–2643.PubMedCrossRefGoogle Scholar
  31. Chong, K.T., Pagano, P.J. and Hinshaw, R.R., (1994), Bisheteroarylpiperazine reverse transcriptase inhibitor in combination with 3’-azido-3’-deoxythymidine or 2’,3’-dideoxycytidine synergistically inhibits human immunodeficiency virus type 1 replication in vitro. Antimicrob Agents Chemother, 38, 288–293.PubMedGoogle Scholar
  32. Clevenbergh, P., Bozonnat, M.C., Kirstetter, M., Durant, J., Cua, E., del Giudice, P., Montagne, N. and Simonet, P., (2003), Variable virological outcomes according to the center providing antiretroviral therapy within the PharmAdapt clinical trial. HIV Clin Trials, 4, 84–91.PubMedCrossRefGoogle Scholar
  33. Coffin, J.M., (1995), HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science, 267, 483–489.PubMedCrossRefGoogle Scholar
  34. Colgrove, R. and Japour, A., (1999), A combinatorial ledge: reverse transcriptase fidelity, total body viral burden, and the implications of multiple-drug HIV therapy for the evolution of antiviral resistance. Antiviral Res, 41, 45–56.PubMedCrossRefGoogle Scholar
  35. Colgrove, R.C., Pitt, J., Chung, P.H., Welles, S.L. and Japour, A.J., (1998), Selective vertical transmission of HIV-1 antiretroviral resistance mutations. AIDS, 12, 2281–2288.PubMedCrossRefGoogle Scholar
  36. Colonno, R., Rose, R., McLaren, C., Thiry, A., Parkin, N. and Friborg, J., (2004), Identification of I50L as the signature atazanavir (ATV)-resistance mutation in treatment-naive HIV-1-infected patients receiving ATV-containing regimens. J Infect Dis, 189, 1802–1810.PubMedCrossRefGoogle Scholar
  37. Condra, J., (1998), Virologic and clinical implications of resistance to HIV-1 protease inhibitors. Drug Resist Updat, 1, 292–299.PubMedCrossRefGoogle Scholar
  38. Cornelissen, M., van den Burg, R., Zorgdrager, F., Lukashov, V. and Goudsmit, J., (1997), pol gene diversity of five human immunodeficiency virus type 1 subtypes: evidence for naturally occurring mutations that contribute to drug resistance, limited recombination patterns, and common ancestry for subtypes B and D. J Virol, 71, 6348–6358.PubMedGoogle Scholar
  39. D’Aquila, R.T., Schapiro, J.M., Brun-Vezinet, F., Clotet, B., Conway, B., Demeter, L.M., Grant, R.M., Johnson, V.A., Kuritzkes, D.R., Loveday, C., Shafer, R.W. and Richman, D.D., (2003), Drug resistance mutations in HIV-1. Top HIV Med, 11, 92–96.PubMedGoogle Scholar
  40. Daar, E.S. and Richman, D.D., (2005), Confronting the emergence of drug-resistant HIV type 1: impact of antiretroviral therapy on individual and population resistance. AIDS Res Hum Retroviruses, 21, 343–357.PubMedCrossRefGoogle Scholar
  41. de Jong, M.D., Schuurman, R., Lange, J.M. and Boucher, C.A., (1996), Replication of a pre-existing resistant HIV-1 subpopulation in vivo after introduction of a strong selective drug pressure. Antivir Ther, 1, 33–41.PubMedGoogle Scholar
  42. de Vreese, K., Kofler-Mongold, V., Leutgeb, C., Weber, V., Vermeire, K., Schacht, S., Anne, J., de Clercq, E., Datema, R. and Werner, G., (1996), The molecular target of bicyclams, potent inhibitors of human immunodeficiency virus replication. J Virol, 70, 689–696.PubMedGoogle Scholar
  43. Dean, M., Carrington, M., Winkler, C., Huttley, G.A., Smith, M.W., Allikmets, R., Goedert, J.J., Buchbinder, S.P., Vittinghoff, E., Gomperts, E., Donfield, S., Vlahov, D., Kaslow, R., Saah, A., Rinaldo, C., Detels, R., O’Brien, S.J., (1996), Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science, 273, 1856–1862.PubMedCrossRefGoogle Scholar
  44. Deeks, S.G., (1999), Failure of HIV-1 protease inhibitors to fully suppress viral replication. Implications for salvage therapy. Adv Exp Med Biol, 458, 175–182.PubMedGoogle Scholar
  45. Deeks, S.G., (2001), International perspectives on antiretroviral resistance. Nonnucleoside reverse transcriptase inhibitor resistance. J Acquir Immune Defic Syndr, 26 (Suppl 1), S25–S33.PubMedCrossRefGoogle Scholar
  46. DeGruttola, V., Dix, L., D’Aquila, R., Holder, D., Phillips, A., Ait-Khaled, M., Baxter, J., Clevenbergh, P., Hammer, S., Harrigan, R., Katzenstein, D., Lanier, R., Miller, M., Para, M., Yerly, S., Zolopa, A., Murray, J., Patick, A., Miller, V., Castillo, S., Pedneault, L. and Mellors, J., (2000), The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan. Antivir Ther, 5, 41–48.PubMedGoogle Scholar
  47. Derdeyn, C.A., Decker, J.M., Sfakianos, J.N., Wu, X., O’Brien, W.A., Ratner, L., Kappes, J.C., Shaw, G.M. and Hunter, E., (2000), Sensitivity of human immunodeficiency virus Type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. J Virol, 74, 8358–8367.PubMedCrossRefGoogle Scholar
  48. Descamps, D., Collin, G., Letourneur, F., Apetrei, C., Damond, F., Loussert-Ajaka, I., Simon, F., Saragosti, S., Brun-Vezinet, F., (1997), Susceptibility of human immunodeficiency virus type 1 group O isolates to antiretroviral agents: in vitro phenotypic and genotypic analyses. J Virol, 71, 8893–8898.PubMedGoogle Scholar
  49. Descamps, D., Collin, G., Loussert-Ajaka, I., Saragosti, S., Simon, F. and Brun-Vezinet, F., (1995), HIV-1 group O sensitivity to antiretroviral drugs. AIDS, 9, 977–978.CrossRefGoogle Scholar
  50. Devereux, H.L., Youle, M., Johnson, M.A. and Loveday, C., (1999), Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy. AIDS, 13, F123–F127.PubMedCrossRefGoogle Scholar
  51. Dickover, R.E., Garratty, E.M., Plaeger, S. and Bryson, Y.J., (2001), Perinatal transmission of major, minor, and multiple maternal human immunodeficiency virus type 1 variants in utero and intrapartum. J Virol, 75, 2194–2203.PubMedCrossRefGoogle Scholar
  52. Ding, J., Das, K., Moereels, H., Koymans, L., Andries, K., Janssen, P.A., Hughes, S.H. and Arnold, E., (1995), Structure of HIV-1 RT/TIBO R 86183 complex reveals similarity in the binding of diverse nonnucleoside inhibitors. Nat Struct Biol, 2, 407–415.PubMedCrossRefGoogle Scholar
  53. Dorr, P., Westby, M., Dobbs, S., Griffin, P., Irvine, B., Macartney, M., Mori, J., Rickett, G., Smith-Burchnell, C., Napier, C., Webster, R., Armour, D., Price, D., Stammen, B., Wood, A. and Perros, M., (2005), Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus Type 1 activity. Antimicrob Agents Chemother, 49, 4721–4732.PubMedCrossRefGoogle Scholar
  54. Doyon, L., Croteau, G., Thibeault, D., Poulin, F., Pilote, L. and Lamarre, D., (1996), Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors. J Virol, 70, 3763–3769.PubMedGoogle Scholar
  55. Doyon, L., Payant, C., Brakier-Gingras, L. and Lamarre, D., (1998), Novel Gag–Pol frameshift site in human immunodeficiency virus type 1 variants resistant to protease inhibitors. J Virol, 72, 6146–6150.PubMedGoogle Scholar
  56. Drosopoulos, W.C., Rezende, L.F., Wainberg, M.A. and Prasad, V.R., (1998), Virtues of being faithful: can we limit the genetic variation in human immunodeficiency virus? J Mol Med, 76, 604–612.PubMedCrossRefGoogle Scholar
  57. Dueweke, T.J., Pushkarskaya, T., Poppe, S.M., Swaney, S.M., Zhao, J.Q., Chen, I.S., Stevenson, M. and Tarpley, W.G., (1993), A mutation in reverse transcriptase of bis(heteroaryl)piperazine-resistant human immunodeficiency virus type 1 that confers increased sensitivity to other nonnucleoside inhibitors. Proc Natl Acad Sci USA, 90, 4713–4717.PubMedCrossRefGoogle Scholar
  58. Durant, J., Clevenbergh, P., Halfon, P., Delgiudice, P., Porsin, S., Simonet, P., Montagne, N., Boucher, C.A., Schapiro, J.M. and Dellamonica, P., (1999), Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet, 353, 2195–2199.PubMedCrossRefGoogle Scholar
  59. Esnouf, R., Ren, J., Ross, C., Jones, Y., Stammers, D. and Stuart, D., (1995), Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors. Nat Struct Biol, 2, 303–308.PubMedCrossRefGoogle Scholar
  60. Este, J.A., Cabrera, C., Blanco, J., Gutierrez, A., Bridger, G., Henson, G., Clotet, B., Schols, D. and De Clercq, E., (1999), Shift of clinical human immunodeficiency virus Type 1 isolates from X4 to R5 and prevention of emergence of the Syncytium-inducing phenotype by blockade of CXCR4. J Virol, 73, 5577–5585.PubMedGoogle Scholar
  61. Ferrer, E., Podzamczer, D., Arnedo, M., Fumero, E., McKenna, P., Rinehart, A., Perez, J.L., Barbera, M.J., Pumarola, T., Gatell, J.M. and Gudiol, F., (2003), Genotype and phenotype at baseline and at failure in human immunodeficiency virus-infected antiretroviral-naive patients in a randomized trial comparing zidovudine and lamivudine plus nelfinavir or nevirapine. J Infect Dis, 187, 687–690.PubMedCrossRefGoogle Scholar
  62. Finzi, D., Blankson, J., Siliciano, J.D., Margolick, J.B., Chadwick, K., Pierson, T., Smith, K., Lisziewicz, J., Lori, F., Flexner, C., Quinn, T.C., Chaisson, R.E., Rosenberg, E., Walker, B., Gange, S., Gallant, J. and Siliciano, R.F., (1999), Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med, 5, 512–517.PubMedCrossRefGoogle Scholar
  63. Fletcher, R.S., Arion, D., Borkow, G., Wainberg, M.A., Dmitrienko, G.I. and Parniak, M.A., (1995), Synergistic inhibition of HIV-1 reverse transcriptase DNA polymerase activity and virus replication in vitro by combinations of carboxanilide nonnucleoside compounds. Biochemistry, 34, 10106–10112.PubMedCrossRefGoogle Scholar
  64. Frost, S.D., Nijhuis, M., Schuurman, R., Boucher, C.A. and Brown, A.J., (2000), Evolution of lamivudine resistance in human immunodeficiency virus type 1-infected individuals: the relative roles of drift and selection. J Virol, 74, 6262–6268.PubMedCrossRefGoogle Scholar
  65. Furman, P.A., Fyfe, J.A., St Clair, M.H., Weinhold, K., Rideout, J.L., Freeman, G.A., Lehrman, S.N., Bolognesi, D.P., Broder, S., Mitsuya, H. and Barry, D.W., (1986), Phosphorylation of 3’-azido-3’-deoxythymidine and selective interaction of the 5’-triphosphate with human immunodeficiency virus reverse transcriptase. Proc Natl Acad Sci USA, 83, 8333–8337.PubMedCrossRefGoogle Scholar
  66. Gandhi, R.T., Wurcel, A., Rosenberg, E.S., Johnston, M.N., Hellmann, N., Bates, M., Hirsch, M.S. and Walker, B.D., (2003), Progressive reversion of human immunodeficiency virus type 1 resistance mutations in vivo after transmission of a multiply drug-resistant virus. Clin Infect Dis, 37, 1693–1698.PubMedCrossRefGoogle Scholar
  67. Gao, Q., Gu, Z., Salomon, H., Nagai, K., Parniak, M.A. and Wainberg, M.A., (1994), Generation of multiple drug resistance by sequential in vitro passage of the human immunodeficiency virus type 1. Arch Virol, 136, 111–122.PubMedCrossRefGoogle Scholar
  68. Gatanaga, H., Suzuki, Y., Tsang, H., Yoshimura, K., Kavlick, M.F., Nagashima, K., Gorelick, R.J., Mardy, S., Tang, C., Summers, M.F. and Mitsuya, H., (2002), Amino acid substitutions in Gag protein at non-cleavage sites are indispensable for the development of a high multitude of HIV-1 resistance against protease inhibitors. J Biol Chem, 277, 5952–5961.PubMedCrossRefGoogle Scholar
  69. Gianotti, N., Mondino, V., Rossi, M.C., Chiesa, E., Mezzaroma, I., Ladisa, N., Guaraldi, G., Torti, C., Tarquini, P., Castelli, P., Di Carlo, A., Boeri, E., Keulen, W., Kenna, P.M. and Lazzarin, A., (2006), Comparison of a rule-based algorithm with a phenotype-based algorithm for the interpretation of HIV genotypes in guiding salvage regimens in HIV-infected patients by a randomized clinical trial: the mutations and salvage study. Clin Infect Dis, 42, 1470–1480.PubMedCrossRefGoogle Scholar
  70. Gonzales, M.J., Delwart, E., Rhee, S.Y., Tsui, R., Zolopa, A.R., Taylor, J. and Shafer, R.W., (2003), Lack of detectable human immunodeficiency virus type 1 superinfection during 1072 person-years of observation. J Infect Dis, 188, 397–405.PubMedCrossRefGoogle Scholar
  71. Gonzalez de Requena, D., Gallego, O., Valer, L., Jimenez-Nacher, I. and Soriano, V., (2004), Prediction of virological response to lopinavir/ritonavir using the genotypic inhibitory quotient. AIDS Res Hum Retroviruses, 20, 275–278.PubMedCrossRefGoogle Scholar
  72. Gotte, M. and Wainberg, M.A., (2000), Biochemical mechanisms involved in overcoming HIV resistance to nucleoside inhibitors of reverse transcriptase. Drug Resist Updat, 3, 30–38.PubMedCrossRefGoogle Scholar
  73. Graham, N., Peeters, M., Verbiest, W., Harrigan, R. and Larder B., (2001), The Virtual Phenotype is an independent predictor of clinical response. Program and abstracts of the 8th Conference on Retroviruses and Opportunistic Infections. 4–8 February 2001, Chicago, USA. Abstract 524.Google Scholar
  74. Greenberg, M., Sista, P., Miralles, G., Melby, T., Davison, D., Jin, L., Mosier, S., Mink, M., Nelson, E., Demasi, R., Fang, L., Cammack, N., Salgo, M., Duff, F., and Matthews, T. for the T1249-101 Study Group, (2002), Enfuvirtide (T-20) and T-1249 resistance: observations from Phase II clinical trials of enfuvirtide in combination with oral antiretrovirals (ARVs) and a Phase I/II dose-ranging monotherapy trial of T-1249. In XI International HIV Drug Resistance Workshop, Seville, Spain, 2–5 July 2002. Abstract 128. Antivir Ther, 7, S106.Google Scholar
  75. Greenberg, M.L., Melby, T., Sista, P., DeMasi, R., Cammack, N., Salgo, M., Whitcomb, J., Petropoulos, C. and Matthews, T., (2003a), Baseline and on-treatment susceptibility to enfuvirtide seen in TORO 1 and TORO 2 through 24 weeks. 10th Conference on Retroviruses and Opportunistic Infections, Boston, USA, 10–14 February 2003. Abstract 141.Google Scholar
  76. Greenberg, M.L., Melby, T., Sista, P., Demasi, R., Cammack, N., Salgo, M., Whitcomb, J., Petropoulos, C. and Matthews, T.J., (2003b), Baseline and on-treatment susceptibility to enfuvirtide seen in TORO 1 and TORO 2 through 24 weeks. 10th Conference on Retroviruses and Opportunistic Infections, Boston, USA, 10–14 February 2003. Abstract 141.Google Scholar
  77. Gu, Z., Quan, Y., Li, Z., Arts, E.J. and Wainberg, M.A., (1995), Effects of non-nucleoside inhibitors of human immunodeficiency virus type 1 in cell-free recombinant reverse transcriptase assays. J Biol Chem, 270, 31046–31051.PubMedCrossRefGoogle Scholar
  78. Gunthard, H.F., Wong, J.K., Ignacio, C.C., Guatelli, J.C., Riggs, N.L., Havlir, D.V. and Richman, D.D., (1998), Human immunodeficiency virus replication and genotypic resistance in blood and lymph nodes after a year of potent antiretroviral therapy. J Virol, 72, 2422–2428.PubMedGoogle Scholar
  79. Hart, G.J., Orr, D.C., Penn, C.R., Figueiredo, H.T., Gray, N.M., Boehme, R.E. and Cameron, J.M., (1992), Effects of (–)-2’-deoxy-3’-thiacytidine (3TC) 5’-triphosphate on human immunodeficiency virus reverse transcriptase and mammalian DNA polymerases alpha, beta, and gamma. Antimicrob Agents Chemother, 36, 1688–1694.PubMedGoogle Scholar
  80. He, Y., Vassell, R., Zaitseva, M., Nguyen, N., Yang, Z., Weng, Y. and Weiss, C.D., (2003), Peptides trap the human immunodeficiency virus Type 1 envelope glycoprotein fusion intermediate at two sites. J Virol, 77, 1666–1671.PubMedCrossRefGoogle Scholar
  81. Hecht, F.M., Grant, R.M., Petropoulos, C.J., Dillon, B., Chesney, M.A., Tian, H., Hellmann, N.S., Bandrapalli, N.I., Digilio, L., Branson, B. and Kahn, J.O., (1998), Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors. N Engl J Med, 339, 307–311.PubMedCrossRefGoogle Scholar
  82. Hertogs, K., Bloor, S., Kemp, S.D., Van den Eynde, C., Alcorn, T.M., Pauwels, R., Van Houtte, M., Staszewski, S., Miller, V. and Larder, B.A., (2000), Phenotypic and genotypic analysis of clinical HIV-1 isolates reveals extensive protease inhibitor cross-resistance: a survey of over 6000 samples. AIDS, 14, 1203–1210.PubMedCrossRefGoogle Scholar
  83. Hirsch, M.S., Brun-Vezinet, F., Clotet, B., Conway, B., Kuritzkes, D.R., D’Aquila, R.T., Demeter, L.M., Hammer, S.M., Johnson, V.A., Loveday, C., Mellors, J.W., Jacobsen, D.M. and Richman, D.D., (2003), Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. Clin Infect Dis, 37, 113–128.PubMedCrossRefGoogle Scholar
  84. Holguin, A. and Soriano, V., (2002), Resistance to antiretroviral agents in individuals with HIV-1 non-B subtypes. HIV Clin Trials, 3, 403–411.PubMedCrossRefGoogle Scholar
  85. Japour, A.J., Mayers, D.L., Johnson, V.A., Kuritzkes, D.R., Beckett, L.A., Arduino, J.M., Lane, J., Black, R.J., Reichelderfer, P.S., D’Aquila, R.T. and Crumpacker, C.S., (1993), Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. The RV-43 Study Group, the AIDS Clinical Trials Group Virology Committee Resistance Working Group. Antimicrob Agents Chemother, 37, 1095–1101.PubMedGoogle Scholar
  86. Jennings, C.L., Bosch, R.J., Dragavon, J., Kabat, W., Shugarts, D.L., Boone, L., Decker, W.D., Givens, M.R., Lambrecht, L., Bick, C.T.S., DiFrancesco, R., Hartman, K.E., Cooper, M., Kondo, P.K., Medvik, K.A., Sepelak, S., Tustin, N., Kaczmarek, M., Yanavich, C., Mong-Kryspin, L., Siminski, S., Vincent, C.A., Kerkau, M.G., Livnat, D., Piwowar-Manning, E.M. and Tooley, K., (2004), The virology manual for HIV laboratories. National Institute for Allergy and Infectious Disease. Available at Scholar
  87. Johnson, V.A., Brun-Vezinet, F., Clotet, B., Conway, B., Kuritzkes, D.R., Pillay, D., Schapiro, J.M., Telenti, A. and Richman, D.D., (2005), Update of the drug resistance mutations in HIV-1: Fall 2005. Top HIV Med, 13, 125–131.PubMedGoogle Scholar
  88. Jonckheere, H., Taymans, J.M., Balzarini, J., Velazquez, S., Camarasa, M.J., Desmyter, J., De Clercq, E. and Anne, J., (1994), Resistance of HIV-1 reverse transcriptase against [2’,5’-bis-O-(tert-butyldimethylsilyl)-3’-spiro-5”-(4”-amino-1”,2”- oxathiole-2”,2”-dioxide)] (TSAO) derivatives is determined by the mutation Glu138⇒Lys on the p51 subunit. J Biol Chem, 269, 25255–25258.PubMedGoogle Scholar
  89. Jost, S., Bernard, M.-C., Kaiser, L., Yerly, S., Hirschel, B., Samri, A., Autran, B., Goh, L.-E. and Perrin, L., (2002), A Patient with HIV-1 Superinfection. N Engl J Med, 347, 731–736.PubMedCrossRefGoogle Scholar
  90. Kantor, R., Zijenah, L.S., Shafer, R.W., Mutetwa, S., Johnston, E., Lloyd, R., von Lieven, A., Israelski, D. and Katzenstein, D.A., (2002), HIV-1 subtype C reverse transcriptase and protease genotypes in Zimbabwean patients failing antiretroviral therapy. AIDS Res Hum Retroviruses, 18, 1407–1413.PubMedCrossRefGoogle Scholar
  91. Kitrinos, K., LaBranche, C., Stanhope, M., Madsen, H. and Demarest, J., (2005), Clonal analysis detects pre-existing R5X4-tropic virus in patient demonstrating populations-level tropism shift on 873140 monotherapy. Antivir Ther, 10, S68. Abstract 61.Google Scholar
  92. Koelsch, K.K., Smith, D.M., Little, S.J., Ignacio, C.C., Macaranas, T.R., Brown, A.J., Petropoulos, C.J., Richman, D.D. and Wong, J.K.,(2003), Clade B HIV-1 superinfection with wild-type virus after primary infection with drug-resistant clade B virus. AIDS, 17, F11–F16.Google Scholar
  93. Kuhmann, S.E., Pugach, P., Kunstman, K.J., Taylor, J., Stanfield, R.L., Snyder, A., Strizki, J.M., Riley, J., Baroudy, B.M., Wilson, I.A., Korber, B.T., Wolinsky, S.M. and Moore, J.P., (2004), Genetic and phenotypic analyses of human immunodeficiency virus Type 1 escape from a small-molecule CCR5 inhibitor. J Virol, 78, 2790–2807.PubMedCrossRefGoogle Scholar
  94. Lalezari, J.P., DeJesus, E., Northfelt, D.W., Richmond, G., Wolfe, P., Haubrich, R., Henry, D., Powderly, W., Becker, S., Thompson, M., Valentine, F., Wright, D., Carlson, M., Riddler, S., Haas, F.F., DeMasi, R., Sista, P.R., Salgo, M. and Delehanty, J., (2003a), A controlled Phase II trial assessing three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir, ritonavir and efavirenz in non-nucleoside reverse transcriptase inhibitor-naive HIV-infected adults. Antivir Ther, 8, 279–287.Google Scholar
  95. Lalezari, J.P., Eron, J.J., Carlson, M., Cohen, C., DeJesus, E., Arduino, R.C., Gallant, J.E., Volberding, P., Murphy, R.L., Valentine, F., Nelson, E.L., Sista, P.R., Dusek, A. and Kilby, J.M., (2003b), A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy. AIDS, 17, 691–698.CrossRefGoogle Scholar
  96. Lalezari, J.P., Henry, K., O’Hearn, M., Montaner, J.S.G., Piliero, P.J., Trottier, B., Walmsley, S., Cohen, C., Kuritzkes, D.R., Eron, J.J., Jr, Chung, J., DeMasi, R., Donatacci, L., Drobnes, C., Delehanty, J., Salgo, M. and the TSG, (2003c), Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med, 348, 2175–2185.CrossRefGoogle Scholar
  97. Larder, B.A., Kemp, S.D., and Hertogs, K., (2000), Quantitative prediction of HIV-1 phenotypic drug resistance from genotypes: the virtual phenotype (VirtualPhenotype). Antiviral Ther, 5 (Suppl 3), 49. Abstract 63.Google Scholar
  98. Lazzarin, A., Clotet, B., Cooper, D., Reynes, J., Arasteh, K., Nelson, M., Katlama, C., Stellbrink, H.-J., Delfraissy, J.-F., Lange, J., Huson, L., DeMasi, R., Wat, C., Delehanty, J., Drobnes, C., Salgo, M. and the TSG, (2003), Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med, 348, 2186–2195.PubMedCrossRefGoogle Scholar
  99. Lederman, M.M., Offord, R.E. and Hartley, O., (2006), Microbicides and other topical strategies to prevent vaginal transmission of HIV. Nat Rev Immunol, 6, 371–382.PubMedCrossRefGoogle Scholar
  100. Lehrman, G., Hogue, I.B., Palmer, S., Jennings, C., Spina, C.A., Wiegand, A., Landay, A.L., Coombs, R.W., Richman, D.D., Mellors, J.W., Coffin, J.M., Bosch, R.J. and Margolis, D.M., (2005), Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet, 366, 549–555.PubMedCrossRefGoogle Scholar
  101. Liang, C., Rong, L., Quan, Y., Laughrea, M., Kleiman, L. and Wainberg, M.A., (1999), Mutations within four distinct gag proteins are required to restore replication of human immunodeficiency virus type 1 after deletion mutagenesis within the dimerization initiation site. J Virol, 73, 7014–7020.PubMedGoogle Scholar
  102. Little, S.J., Holte, S., Routy, J.P., Daar, E.S., Markowitz, M., Collier, A.C., Koup, R.A., Mellors, J.W., Connick, E., Conway, B., Kilby, M., Wang, L., Whitcomb, J.M., Hellmann, N.S. and Richman, D.D., (2002), Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med, 347, 385–394.PubMedCrossRefGoogle Scholar
  103. Loemba, H., Brenner, B., Parniak, M.A., Ma’ayan S, Spira, B., Moisi, D., Oliveira, M., Detorio, M. and Wainberg, M.A., (2002), Genetic divergence of human immunodeficiency virus type 1 Ethiopian clade C reverse transcriptase (RT) and rapid development of resistance against nonnucleoside inhibitors of RT. Antimicrob Agents Chemother, 46, 2087–2094.PubMedCrossRefGoogle Scholar
  104. Logsdon, B.C., Vickrey, J.F., Martin, P., Proteasa, G., Koepke, J.I., Terlecky, S.R., Wawrzak, Z., Winters, M.A., Merigan, T.C. and Kovari, L.C., (2004), Crystal structures of a multidrug-resistant human immunodeficiency virus Type 1 protease reveal an expanded active-site cavity. J Virol, 78, 3123–3132.PubMedCrossRefGoogle Scholar
  105. Lorenzi, P., Opravil, M., Hirschel, B., Chave, J.P., Furrer, H.J., Sax, H., Perneger, T.V., Perrin, L., Kaiser, L. and Yerly, S., (1999), Impact of drug resistance mutations on virologic response to salvage therapy. Swiss HIV Cohort Study. AIDS, 13, F17–F21.PubMedCrossRefGoogle Scholar
  106. Loveday, C., (2001), International perspectives on antiretroviral resistance. Nucleoside reverse transcriptase inhibitor resistance. J Acquir Immune Defic Syndr, 26 (Suppl 1), S10–S24.PubMedCrossRefGoogle Scholar
  107. Loya, S., Bakhanashvili, M., Tal, R., Hughes, S.H., Boyer, P.L. and Hizi, A., (1994), Enzymatic properties of two mutants of reverse transcriptase of human immunodeficiency virus type 1 (tyrosine 181⇒isoleucine and tyrosine 188⇒leucine), resistant to nonnucleoside inhibitors. AIDS Res Hum Retroviruses, 10, 939–946.PubMedGoogle Scholar
  108. Lu, J., Sista, P., Giguel, F., Greenberg, M. and Kuritzkes, D.R., (2004), Relative replicative fitness of human immunodeficiency virus Type 1 mutants resistant to enfuvirtide (T-20). J Virol, 78, 4628–4637.PubMedCrossRefGoogle Scholar
  109. Mangeat, B., Turelli, P., Caron, G., Friedli, M., Perrin, L. and Trono, D., (2003), Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature, 424, 99–103.PubMedCrossRefGoogle Scholar
  110. Mansky, L.M., (2002), HIV mutagenesis and the evolution of antiretroviral drug resistance. Drug Resist Updat, 5, 219–223.PubMedCrossRefGoogle Scholar
  111. Mansky, L.M., Le Rouzic, E., Benichou, S., Gajary, L.C., (2003), Influence of reverse transcriptase variants, drugs, and Vpr on human immunodeficiency virus type 1 mutant frequencies. J Virol, 77, 2071–2080.PubMedCrossRefGoogle Scholar
  112. Marcelin, A.G., Lamotte, C., Delaugerre, C., Ktorza, N., Ait Mohand, H., Cacace, R., Bonmarchand, M., Wirden, M., Simon, A., Bossi, P., Bricaire, F., Costagliola, D., Katlama, C., Peytavin, G. and Calvez, V., (2003), Genotypic inhibitory quotient as predictor of virological response to ritonavir–amprenavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients. Antimicrob Agents Chemother, 47, 594–600.PubMedCrossRefGoogle Scholar
  113. Mariani, R., Chen, D., Schrofelbauer, B., Navarro, F., Konig, R., Bollman, B., Munk, C., Nymark-McMahon, H. and Landau, N.R., (2003), Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif. Cell, 114, 21–31.PubMedCrossRefGoogle Scholar
  114. Markham, R.B., Wang, W.-C., Weisstein, A.E., Wang, Z., Munoz, A., Templeton, A., Margolick, J., Vlahov, D., Quinn, T., Farzadegan, H. and Yu, X.-F., (1998), Patterns of HIV-1 evolution in individuals with differing rates of CD4 T cell decline. Proc Nat Acad Sci USA, 95, 12568–12573.PubMedCrossRefGoogle Scholar
  115. Marozsan, A.J., Kuhmann, S.E., Morgan, T., Herrera, C., Rivera-Troche, E., Xu, S., Baroudy, B.M., Strizki, J. and Moore, J.P., (2005), Generation and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D). Virology, 338, 182.PubMedCrossRefGoogle Scholar
  116. Martin, P., Vickrey, J.F., Proteasa, G., Jimenez, Y.L., Wawrzak, Z., Winters, M.A., Merigan, T.C. and Kovari, L.C., (2005), “Wide-Open” 1.3 A Structure of a Multidrug-Resistant HIV-1 Protease as a Drug Target. Structure. 13, 1887–1895.Google Scholar
  117. Martinez-Picado, J., Savara, A.V., Sutton, L. and D’Aquila, R.T., (1999), Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1. J Virol, 73, 3744–3752.PubMedGoogle Scholar
  118. Martinez, J.L., McArthur, R., VIckrey, J., Martin, P., Proteasa, G., Kondapalli, K., Jimenez, Y., Wawrzak, W., Winters, M., Merigan, T. and Kovari, L., (2004), The Multi-Drug Resistance Protease Represents a Novel Drug Target 44th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society of Microbiology, Washington, DC, USA.Google Scholar
  119. Mayers, D.L., (1997), Prevalence and incidence of resistance to zidovudine and other antiretroviral drugs. Am J Med, 102, 70–75.PubMedCrossRefGoogle Scholar
  120. Mazzotta, F., Lo Caputo, S., Torti, C., Tinelli, C., Pierotti, P., Castelli, F., Lazzarin, A., Angarano, G., Maserati, R., Gianotti, N., Ladisa, N., Quiros-Roldan, E., Rinehart, A.R. and Carosi, G., (2003), Real versus virtual phenotype to guide treatment in heavily pretreated patients: 48-week follow-up of the Genotipo-Fenotipo di Resistenza (GenPheRex) trial. J Acquir Immune Defic Syndr, 32, 268–280.PubMedCrossRefGoogle Scholar
  121. Menendez-Arias, L., (2002), Molecular basis of fidelity of DNA synthesis and nucleotide specificity of retroviral reverse transcriptases. Prog Nucleic Acid Res Mol Biol, 71, 91–147.PubMedCrossRefGoogle Scholar
  122. Menzo, S., Castagna, A., Monachetti, A., Hasson, H., Danise, A., Carini, E., Bagnarelli, P., Lazzarin, A. and Clementi, M., (2004), Resistance and replicative capacity of HIV-1 strains selected in vivo by long-term enfuvirtide treatment. New Microbiol, 27, 51–61.PubMedGoogle Scholar
  123. Mink, M., Greenberg, M., Mosier, S., Janumpalli, S., Davison, D., Jin, L., Melby, T., Sista, P., Lambert, D., Cammack, N., Salgo, M. and Matthews, T., (2002), Impact of HIV-1 gp41 amino acid substitutions (positions 36–45) on susceptibility to T-20 (enfuvirtide) in vitro: analysis of primary virus isolates recovered from patients during chronic enfuvirtide treatment and site directed mutants in NL4-3. In XI International HIV Drug Resistance Workshop, Seville, Spain, 2–5 July 2002. Abstract 22. Antivir Ther, 7, S17.Google Scholar
  124. Molla, A., Korneyeva, M., Gao, Q., Vasavanonda, S., Schipper, P.J., Mo, H.M., Markowitz, M., Chernyavskiy, T., Niu, P., Lyons, N., Hsu, A., Granneman, G.R., Ho, D.D., Boucher, C.A., Leonard, J.M., Norbeck, D.W. and Kempf, D.J., (1996), Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat Med, 2, 760–766.PubMedCrossRefGoogle Scholar
  125. Murphy, R.L., (1999), New antiretroviral drugs part I: PIs. AIDS Clin Care, 11, 35–37.PubMedGoogle Scholar
  126. Myint, L., Matsuda, M., Matsuda, Z., Yokomaku, Y., Chiba, T., Okano, A., Yamada, K. and Sugiura, W., (2004), Gag non-cleavage site mutations contribute to full recovery of viral fitness in protease inhibitor-resistant human immunodeficiency virus type 1. Antimicrob Agents Chemother, 48, 444–452.PubMedCrossRefGoogle Scholar
  127. Nijhuis, M., Deeks, S. and Boucher, C., (2001), Implications of antiretroviral resistance on viral fitness. Curr Opin Infect Dis, 14, 23–28.PubMedCrossRefGoogle Scholar
  128. Nunberg, J.H., Schleif, W.A., Boots, E.J., O’Brien, J.A., Quintero, J.C., Hoffman, J.M., Emini, E.A. and Goldman, M.E., (1991), Viral resistance to human immunodeficiency virus type 1-specific pyridinone reverse transcriptase inhibitors. J Virol, 65, 4887–4892.PubMedGoogle Scholar
  129. Ohtaka, H., Velazquez-Campoy, A., Xie, D. and Freire, E., (2002), Overcoming drug resistance in HIV-1 chemotherapy: the binding thermodynamics of Amprenavir and TMC-126 to wild-type and drug-resistant mutants of the HIV-1 protease. Protein Sci, 11, 1908–1916.PubMedCrossRefGoogle Scholar
  130. Ormaasen, V., Sandvik, L., Asjo, B., Holberg-Petersen, M., Gaarder, P.I. and Bruun, J.N., (2004), An algorithm-based genotypic resistance score is associated with clinical outcome in HIV-1-infected adults on antiretroviral therapy. HIV Med, 5, 400–406.PubMedCrossRefGoogle Scholar
  131. Overbaugh, J. and Bangham, C.R., (2001), Selection forces and constraints on retroviral sequence variation. Science, 292, 1106–1109.PubMedCrossRefGoogle Scholar
  132. Palella, F.J., Jr, Delaney, K.M., Moorman, A.C., Loveless, M.O., Fuhrer, J., Satten, G.A., Aschman, D.J. and Holmberg, S.D., (1998), Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med, 338, 853–860.PubMedCrossRefGoogle Scholar
  133. Palmer, S., Alaeus, A., Albert, J. and Cox, S., (1998), Drug susceptibility of subtypes A,B,C,D, and E human immunodeficiency virus type 1 primary isolates. AIDS Res Hum Retroviruses, 14, 157–162.PubMedCrossRefGoogle Scholar
  134. Palmer, S., Shafer, R.W. and Merigan, T.C., (1999), Highly drug-resistant HIV-1 clinical isolates are cross-resistant to many antiretroviral compounds in current clinical development. AIDS, 13, 661–667.PubMedCrossRefGoogle Scholar
  135. Panidou, E.T., Trikalinos, T.A., Ioannidis, J.P., (2004), Limited benefit of antiretroviral resistance testing in treatment-experienced patients: a meta-analysis. AIDS, 18, 2153–2161.PubMedCrossRefGoogle Scholar
  136. Patick, A.K., Duran, M., Cao, Y., Shugarts, D., Keller, M.R., Mazabel, E., Knowles, M., Chapman, S., Kuritzkes, D.R. and Markowitz, M., (1998), Genotypic and phenotypic characterization of human immunodeficiency virus Type 1 variants isolated from patients treated with the protease inhibitor nelfinavir. Antimicrob Agents Chemother, 42, 2637–2644.PubMedGoogle Scholar
  137. Perez-Alvarez, L., Carmona, R., Ocampo, A., Asorey, A., Miralles, C., Perez de Castro, S., Pinilla, M., Contreras, G., Taboada, J.A. and Najera, R., (2006), Long-term monitoring of genotypic and phenotypic resistance to T20 in treated patients infected with HIV-1. J Med Virol, 78, 141–147.PubMedCrossRefGoogle Scholar
  138. Petrella, M., Brenner, B., Loemba, H. and Wainberg, M.A., (2001), HIV drug resistance and implications for the introduction of antiretroviral therapy in resource-poor countries. Drug Resist Updat, 4, 339–346.PubMedCrossRefGoogle Scholar
  139. Petrella, M., Wainberg, M.A., (2002), Might the M184V substitution in HIV-1 RT confer clinical benefit? AIDS Rev 4:224–232.PubMedGoogle Scholar
  140. Phillips, A., (2001), Will the drugs still work? Transmission of resistant HIV. Nat Med, 7, 993–994.PubMedCrossRefGoogle Scholar
  141. Poveda, E., Rodes, B., Labernardiere, J.L., Benito, J.M., Toro, C., Gonzalez-Lahoz, J., Faudon, J.L., Clavel, F., Schapiro, J. and Soriano, V., (2004), Evolution of genotypic and phenotypic resistance to Enfuvirtide in HIV-infected patients experiencing prolonged virologic failure. J Med Virol, 74, 21–28.PubMedCrossRefGoogle Scholar
  142. Poveda, E., Rodes, B., Lebel-Binay, S., Faudon, J.-L., Jimenez, V. and Soriano, V., (2005), Dynamics of enfuvirtide resistance in HIV-infected patients during and after long-term enfuvirtide salvage therapy. Focus on HIV, 34, 295.Google Scholar
  143. Preston, B.D. and Dougherty, J.P., (1996), Mechanisms of retroviral mutation. Trends Microbiol, 4, 16–21.PubMedCrossRefGoogle Scholar
  144. Quinn, T.C., Wawer, M.J., Sewankambo, N., Serwadda, D., Li, C., Wabwire-Mangen, F., Meehan, M.O., Lutalo, T. and Gray, R.H., (2000), Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med, 342, 921–929.PubMedCrossRefGoogle Scholar
  145. Quiros-Roldan, E., Signorini, S., Castelli, F., Torti, C., Patroni, A., Airoldi, M. and Carosi, G., (2001), Analysis of HIV-1 mutation patterns in patients failing antiretroviral therapy. J Clin Lab Anal, 15, 43–46.PubMedCrossRefGoogle Scholar
  146. Ramos, A., Hu, D.J., Nguyen, L., Phan, K.O., Vanichseni, S., Promadej, N., Choopanya, K., Callahan, M., Young, N.L., McNicholl, J., Mastro, T.D., Folks, T.M. and Subbarao, S., (2002), Intersubtype human immunodeficiency virus type 1 superinfection following seroconversion to primary infection in two injection drug users. J Virol, 76, 7444–7452.PubMedCrossRefGoogle Scholar
  147. Reeves, J.D., Gallo, S.A., Ahmad, N., Miamidian, J.L., Harvey, P.E., Sharron, M., Pohlmann, S., Sfakianos, J.N., Derdeyn, C.A., Blumenthal, R., Hunter, E. and Doms, R.W., (2002), Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics. Proc Natl Acad Sci, 99, 16249–16254.PubMedCrossRefGoogle Scholar
  148. Reeves, J.D., Lee, F.-H., Miamidian, J.L., Jabara, C.B., Juntilla, M.M. and Doms, R.W., (2005), Enfuvirtide resistance mutations: impact on human immunodeficiency virus envelope function, entry inhibitor sensitivity, and virus neutralization. J Virol, 79, 4991–4999.PubMedCrossRefGoogle Scholar
  149. Resch, W., Ziermann, R., Parkin, N., Gamarnik, A. and Swanstrom, R., (2002), Nelfinavir-resistant, amprenavir-hypersusceptible strains of human immunodeficiency virus Type 1 carrying an N88S mutation in protease have reduced infectivity, reduced replication capacity, and reduced fitness and process the gag polyprotein precursor aberrantly. J Virol, 76, 8659–8666.PubMedCrossRefGoogle Scholar
  150. Rezende, L.F., Drosopoulos, W.C. and Prasad, V.R., (1998), The influence of 3TC resistance mutation M184I on the fidelity and error specificity of human immunodeficiency virus type 1 reverse transcriptase. Nucleic Acids Res, 26, 3066–3072.PubMedCrossRefGoogle Scholar
  151. Richman, D., Shih, C.K., Lowy, I., Rose, J., Prodanovich, P., Goff, S. and Griffin, J., (1991), Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture. Proc Natl Acad Sci USA, 88, 11241–11245.PubMedCrossRefGoogle Scholar
  152. Rimsky, L.T., Shugars, D.C. and Matthews, T.J., (1998), Determinants of human immunodeficiency virus Type 1 resistance to gp41-derived inhibitory peptides. J Virol, 72, 986–993.PubMedGoogle Scholar
  153. Roberts, J.D., Bebenek, K. and Kunkel, T.A., (1988), The accuracy of reverse transcriptase from HIV-1. Science, 242, 1171–1173.PubMedCrossRefGoogle Scholar
  154. Rousseau, M.N., Vergne, L., Montes, B., Peeters, M., Reynes, J., Delaporte, E. and Segondy, M., (2001), Patterns of resistance mutations to antiretroviral drugs in extensively treated HIV-1-infected patients with failure of highly active antiretroviral therapy. J Acquir Immune Defic Syndr, 26, 36–43.PubMedGoogle Scholar
  155. Salomon, H., Wainberg, M.A., Brenner, B., Quan, Y., Rouleau, D., Cote, P., LeBlanc, R., Lefebvre, E., Spira, B., Tsoukas, C., Sekaly, R.P., Conway, B., Mayers, D. and Routy, J.P., (2000), Prevalence of HIV-1 resistant to antiretroviral drugs in 81 individuals newly infected by sexual contact or injecting drug use. Investigators of the Quebec Primary Infection Study. AIDS, 14, F17–F23.PubMedCrossRefGoogle Scholar
  156. Saracino, A., Monno, L., Locaputo, S., Torti, C., Scudeller, L., Ladisa, N., Antinori, A., Sighinolfi, L., Chirianni, A., Mazzotta, F., Carosi, G. and Angarano, G., (2004), Selection of antiretroviral therapy guided by genotypic or phenotypic resistance testing: an open-label, randomized, multicenter study (PhenGen). J Acquir Immune Defic Syndr, 37, 1587–1598.PubMedCrossRefGoogle Scholar
  157. Sardana, V.V., Emini, E.A., Gotlib, L., Graham, D.J., Lineberger, D.W., Long, W.J., Schlabach, A.J., Wolfgang, J.A. and Condra, J.H., (1992), Functional analysis of HIV-1 reverse transcriptase amino acids involved in resistance to multiple nonnucleoside inhibitors. J Biol Chem, 267, 17526–17530.PubMedGoogle Scholar
  158. Sax, P.E., Islam, R., Walensky, R.P., Losina, E., Weinstein, M.C., Goldie, S.J., Sadownik, S.N. and Freedberg, K.A., (2005), Should resistance testing be performed for treatment-naive HIV-infected patients? A cost-effectiveness analysis. Clin Infect Dis, 41, 1316–1323.PubMedCrossRefGoogle Scholar
  159. Schinazi, R.F., Larder, B.A. and Mellors, A.W., (2000), Mutations in retroviral genes associated in drug resistance: 2000–2001 update. Int Antiviral News, 8, 65–91.Google Scholar
  160. Schols, D., Este, J.A., Cabrera, C. and De Clercq, E., (1998), T-Cell-line-tropic human immunodeficiency virus Type 1 that is made resistant to stromal cell-derived factor 1alpha contains mutations in the envelope gp120 but does not show a switch in coreceptor use. J Virol, 72, 4032–4037.PubMedGoogle Scholar
  161. Shafer, R.W., Eisen, J.A., Merigan, T.C. and Katzenstein, D.A., (1997), Sequence and drug susceptibility of subtype C reverse transcriptase from human immunodeficiency virus type 1 seroconverters in Zimbabwe. J Virol, 71:5441–5448.PubMedGoogle Scholar
  162. Shafer, R.W., Jung, D.R., Betts, B.J., Xi, Y. and Gonzales, M.J., (2000), Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucl Acids Res, 28, 346–348.PubMedCrossRefGoogle Scholar
  163. Shafer, R.W., Winters, M.A., Palmer, S. and Merigan, T.C., (1998), Multiple Concurrent reverse transcriptase and protease mutations and multidrug resistance of HIV-1 isolates from heavily treated patients. Ann Intern Med, 128, 906–911.PubMedGoogle Scholar
  164. Shulman, N., Zolopa, A., Havlir, D., Hsu, A., Renz, C., Boller, S., Jiang, P., Rode, R., Gallant, J., Race, E., Kempf, D.J. and Sun, E., (2002), Virtual inhibitory quotient predicts response to ritonavir boosting of indinavir-based therapy in human immunodeficiency virus-infected patients with ongoing viremia. Antimicrob Agents Chemother, 46, 3907–3916.PubMedCrossRefGoogle Scholar
  165. Sista, P., Melby, T., Greenberg, M., Davison, D., Jin, L., Mosier, S., Mink, M., Nelson, E., Fang, L., Cammack, N., Salgo, M. and Matthews, T., (2002), Characterization of Baseline and Treatment-Emergent Resistance to T-20 (Enfuvirtide) Observed in Phase II Clinical Trials: Substitutions in Gp41 Amino Acids 36–45 and Enfuvirtide Susceptibility of Virus Isolates. In XI International HIV Drug Resistance Workshop, Seville, Spain, 2–5 July 2002. Abstract 21.Google Scholar
  166. Sista, P., Melby, T., Greenberg, M., DeMasi, R., Kuritzkes, D., Nelson, M., Petropoulos, C., Salgo, M., Cammack, N. and Matthews, T., (2003), Subgroup analysis of baseline (BL) susceptibility and early virological response to enfuvirtide in the combined TORO studies. In XII International HIV Drug Resistance Workshop, Los Cabos, Mexico, 10–14 June 2003. Abstract 55.Google Scholar
  167. Sista, P.R., Melby, T., Davison, D., Jin, L., Mosier, S., Mink, M., Nelson, E.L., DeMasi, R., Cammack, N., Salgo, M.P., Matthews, T.J. and Greenberg, M.L., (2004), Characterization of determinants of genotypic and phenotypic resistance to enfuvirtide in baseline and on-treatment HIV-1 isolates. AIDS, 18:, 1787–1794.PubMedCrossRefGoogle Scholar
  168. Smith, D.M., Wong, J.K., Hightower, G.K., Ignacio, C.C., Koelsch, K.K., Daar, E.S., Richman, D.D. and Little, S.J., (2004), Incidence of HIV superinfection following primary infection. JAMA, 292, 1177–1178.PubMedCrossRefGoogle Scholar
  169. Spence, R.A., Kati, W.M., Anderson, K.S. and Johnson, K.A., (1995), Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors. Science, 267, 988–993.PubMedCrossRefGoogle Scholar
  170. Su, C., Heilek-Snyder, G., Fenger, D., Ravindran, P., Tsai, K., Cammack, N., Sista, P. and Chiu, S., (2003), The relationship between susceptibility to enfuvirtide of baseline viral recombinants and polymorphisms in the env region of R5-tropic HIV-1. Antivir Ther, 8, S59.Google Scholar
  171. Tamiya, S., Mardy, S., Kavlick, M.F., Yoshimura, K. and Mistuya, H., (2004), Amino acid insertions near gag cleavage sites restore the otherwise compromised replication of human immunodeficiency virus Type 1 variants resistant to protease inhibitors. J Virol, 78, 12030–12040.PubMedCrossRefGoogle Scholar
  172. Tantillo, C., Ding, J., Jacobo-Molina, A., Nanni, R.G., Boyer, P.L., Hughes, S.H., Pauwels, R., Andries, K., Janssen, P.A. and Arnold, E., (1994), Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance. J Mol Biol, 243, 369–387.PubMedCrossRefGoogle Scholar
  173. Torre, D. and Tambini, R., (2002), Antiretroviral drug resistance testing in patients with HIV-1 infection: a meta-analysis study. HIV Clin Trials, 3, 1–8.PubMedCrossRefGoogle Scholar
  174. Trkola, A., Kuhmann, S.E., Strizki, J.M., Maxwell, E., Ketas, T., Morgan, T., Pugach, P., Xu, S., Wojcik, L., Tagat, J., Palani, A., Shapiro, S., Clader, J.W., McCombie, S., Reyes, G.R., Baroudy, B.M. and Moore, J.P., (2002), HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use. Proc Natl Acad Sci, 99, 395–400.PubMedCrossRefGoogle Scholar
  175. Tsui, R., Herring, B.L., Barbour, J.D., Grant, R.M., Bacchetti, P., Kral, A., Edlin, B.R. and Delwart, E.L., (2004), Human immunodeficiency virus type 1 superinfection was not detected following 215 years of injection drug user exposure. J Virol, 78, 94–103.PubMedCrossRefGoogle Scholar
  176. Tural, C., Ruiz, L., Holtzer, C., Schapiro, J., Viciana, P., Gonzalez, J., Domingo, P., Boucher, C., Rey-Joly, C. and Clotet, B., (2002), Clinical utility of HIV-1 genotyping and expert advice: the Havana trial. AIDS, 16, 209–218.PubMedCrossRefGoogle Scholar
  177. Turner, D., Brenner, B., Routy, J.P., Moisi, D., Rosberger, Z., Roger, M. and Wainberg, M.A., (2004), Diminished representation of HIV-1 variants containing select drug resistance-conferring mutations in primary HIV-1 infection. J Acquir Immune Defic Syndr, 37, 1627–1631.PubMedCrossRefGoogle Scholar
  178. Vandamme, A.M., Debyser, Z., Pauwels, R., De Vreese, K., Goubau, P., Youle, M., Gazzard, B., Stoffels, P.A., Cauwenbergh, G.F. and Anne, J., (1994), Characterization of HIV-1 strains isolated from patients treated with TIBO R82913. AIDS Res Hum Retroviruses, 10, 39–46.PubMedGoogle Scholar
  179. Vandamme, A.M., Sonnerborg, A., Ait-Khaled, M., Albert, J., Asjo, B., Bacheler, L., Banhegyi, D., Boucher, C., Brun-Vezinet, F., Camacho, R., Clevenbergh, P., Clumeck, N., Dedes, N., De Luca, A., Doerr, H.W., Faudon, J.L., Gatti, G., Gerstoft, J., Hall, W.W., Hatzakis, A., Hellmann, N., Horban, A., Lundgren, J.D., Kempf, D., Miller, M., Miller, V., Myers, T.W., Nielsen, C., Opravil, M., Palmisano, L., Perno, C.F., Phillips, A., Pillay, D., Pumarola, T., Ruiz, L., Salminen, M., Schapiro, J., Schmidt, B., Schmit, J.C., Schuurman, R., Shulse, E., Soriano, V., Staszewski, S., Vella, S., Youle, M., Ziermann, R. and Perrin, L., (2004), Updated European recommendations for the clinical use of HIV drug resistance testing. Antivir Ther, 9, 829–848.PubMedGoogle Scholar
  180. Vanden Haesevelde, M., Decourt, J.L., De Leys, R.J., Vanderborght, B., van der Groen, G., van Heuverswijn, H. and Saman, E., (1994), Genomic cloning and complete sequence analysis of a highly divergent African human immunodeficiency virus isolate. J Virol, 68, 1586–1596.PubMedGoogle Scholar
  181. Velazquez-Campoy, A., Muzammil, S., Ohtaka, H., Schon, A., Vega, S. and Freire, E., (2003), Structural and thermodynamic basis of resistance to HIV-1 protease inhibition: implications for inhibitor design. Curr Drug Targets Infect Disord, 3, 311–328.PubMedCrossRefGoogle Scholar
  182. Verhofstede, C., Wanzeele, F.V., Van Der Gucht, B., De Cabooter, N. and Plum, J., (1999), Interruption of reverse transcriptase inhibitors or a switch from reverse transcriptase to protease inhibitors resulted in a fast reappearance of virus strains with a reverse transcriptase inhibitor-sensitive genotype. AIDS, 13, 2541–2546.PubMedCrossRefGoogle Scholar
  183. Wainberg, M.A. and Friedland, G., (1998), Public health implications of antiretroviral therapy and HIV drug resistance. JAMA, 279, 1977–1983.PubMedCrossRefGoogle Scholar
  184. Wainberg, M.A., Hsu, M., Gu, Z., Borkow, G. and Parniak, M.A., (1996), Effectiveness of 3TC in HIV clinical trials may be due in part to the M184V substitution in 3TC-resistant HIV-1 reverse transcriptase. AIDS, 10 (Suppl 5), S3–S10.PubMedGoogle Scholar
  185. Wei, X., Decker, J.M., Liu, H., Zhang, Z., Arani, R.B., Kilby, J.M., Saag, M.S., Wu, X., Shaw, G.M. and Kappes, J.C., (2002), Emergence of resistant human immunodeficiency virus Type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother, 46, 1896–1905.PubMedCrossRefGoogle Scholar
  186. Weinstock, H.S., Zaidi, I., Heneine, W., Bennett, D., Garcia-Lerma, J.G., Douglas, J.M., Jr, LaLota, M., Dickinson, G., Schwarcz, S., Torian, L., Wendell, D., Paul, S., Goza, G.A., Ruiz, J., Boyett, B. and Kaplan, J.E., (2004), The epidemiology of antiretroviral drug resistance among drug-naive HIV-1-infected persons in 10 US cities. J Infect Dis, 189, 2174–2180.PubMedCrossRefGoogle Scholar
  187. Wensing, A.M., van de Vijver, D.A., Angarano, G., Asjo, B., Balotta, C., Boeri, E., Camacho, R., Chaix, M.L., Costagliola, D., De Luca, A., Derdelinckx, I., Grossman, Z., Hamouda, O., Hatzakis, A., Hemmer, R., Hoepelman, A., Horban, A., Korn, K., Kucherer, C., Leitner, T., Loveday, C., MacRae, E., Maljkovic, I., de Mendoza, C., Meyer, L., Nielsen, C., Op de Coul, E.L., Ormaasen, V., Paraskevis, D., Perrin, L., Puchhammer-Stockl, E., Ruiz, L., Salminen, M., Schmit, J.C., Schneider, F., Schuurman, R., Soriano, V., Stanczak, G., Stanojevic, M., Vandamme, A.M., Van Laethem, K., Violin, M., Wilbe, K., Yerly, S., Zazzi, M. and Boucher, C.A., (2005), Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis, 192, 958–966.PubMedCrossRefGoogle Scholar
  188. Westby, M., Lewis, M., Whitcomb, J., Youle, M., Pozniak, A.L., James, I.T., Jenkins, T.M., Perros, M. and van der Ryst, E., (2006), Emergence of CXCR4-using human immunodeficiency virus Type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist Maraviroc is from a pretreatment CXCR4-using virus reservoir. J Virol, 80, 4909–4920.PubMedCrossRefGoogle Scholar
  189. Westby, M., Mori, J., Smith-Burchnell, C., Lewis, M., Mosley, M., Perruccio, F., Mansfield, R., Dorr, P. and Perros, M., (2005), Maraviroc (UK-427,857)-resistant HIV-1 variants, selected by serial passage, are sensitive to CCR5 antagonists and T-20. Antivir Ther, 10, S72.Google Scholar
  190. Westby, M., Smith-Burchnell, C., Mori, J., Lewis, M., Mansfield, R., Whitcomb, J., Petropoulos, C. and Perros, M., (2004a), In vitro escape of R5 primary isolates from the CCR5 antagonist, UK-427,857, is difficult and involves continued use of the CCR5 receptor. In XIII Int. HIV Drug Resist Workshop. Tenerife, Spain. Abstract 6. Antivir Ther, 9, S10.Google Scholar
  191. Westby, M., Whitcomb, J., Huang, W., James, I., Abel, S., Petropoulos, C., Perros, M. and Ryst, E., (2004a), Reversible predominance of CXCR4 using variants in a non-responsive dual tropic patient receiving the CCR5 antagonist UK-427,857. In Eleventh Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, 8–11 February 2004, USA. Abstract 538.Google Scholar
  192. Wheat, L., Lalezari, J., Kilby, M., Wheeler, D., Salgo, M., DeMasi, R. and Delehanty, J., (2002), A week 48 assessment of high strength T-20 formulations in multi-class experienced patients. In 9th Conference on Retroviruses and Opportunistic Infections, Seattle, USA, 24–28 February 2002. Abstract 417-W.Google Scholar
  193. Whitcomb, J., Huang, W., Fransen, S., Wrin, T., Paxind, E., Toma, J., Greenberg, M., Sista, P., Melby, T., Matthews, T., Cammack, N., Hellman, N. and Petropoulus C., (2003), Analysis of baseline enfuvirtide (T-20) susceptibility and co-receptor tropism in two phase III study populations. Tenth Conference on Retroviruses and Opportunistic Infections, Boston, MA, 10–14 February 2003, USA. Abstract 557.Google Scholar
  194. Winston, A., Hales, G., Amin, J., van Schaick, E., Cooper, D.A. and Emery, S., (2005), The normalized inhibitory quotient of boosted protease inhibitors is predictive of viral load response in treatment-experienced HIV-1-infected individuals. AIDS, 19, 1393–1399.PubMedCrossRefGoogle Scholar
  195. Winston, A., Mandalia, S., Pillay, D., Gazzard, B. and Pozniak, A., (2002), The prevalence and determinants of the K65R mutation in HIV-1 reverse transcriptase in tenofovir-naive patients. AIDS, 16, 2087–2089.PubMedCrossRefGoogle Scholar
  196. Winters, M.A., Baxter, J.D., Mayers, D.L., Wentworth, D.N., Hoover, M.L., Neaton, J.D. and Merigan, T.C., (2000), Frequency of antiretroviral drug resistance mutations in HIV-1 strains from patients failing triple drug regimens. The Terry Beirn Community Programs for Clinical Research on AIDS. Antivir Ther, 5, 57–63.PubMedGoogle Scholar
  197. Wong, J.K., Hezareh, M., Gunthard, H.F., Havlir, D.V., Ignacio, C.C., Spina, C.A. and Richman, D.D., (1997), Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science, 278, 1291–1295.PubMedCrossRefGoogle Scholar
  198. Wu, J.C., Warren, T.C., Adams, J., Proudfoot, J., Skiles, J., Raghavan, P., Perry, C., Potocki, I., Farina, P.R. and Grob, P.M., (1991), A novel dipyridodiazepinone inhibitor of HIV-1 reverse transcriptase acts through a nonsubstrate binding site. Biochemistry, 30, 2022–2026.PubMedCrossRefGoogle Scholar
  199. Xu, L., Pozniak, A., Wildfire, A., Stanfield-Oakley, S.A., Mosier, S.M., Ratcliffe, D., Workman, J., Joall, A., Myers, R., Smit, E., Cane, P.A., Greenberg, M.L. and Pillay, D., (2005), Emergence and evolution of enfuvirtide resistance following long-term therapy involves Heptad Repeat 2 mutations within gp41. Antimicrob Agents Chemother, 49, 1113–1119.PubMedCrossRefGoogle Scholar
  200. Yeni, P.G., Hammer, S.M., Carpenter, C.C., Cooper, D.A., Fischl, M.A., Gatell, J.M., Gazzard, B.G., Hirsch, M.S., Jacobsen, D.M., Katzenstein, D.A., Montaner, J.S., Richman, D.D., Saag, M.S., Schechter, M., Schooley, R.T., Thompson, M.A., Vella, S. and Volberding, P.A., (2002), Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA, 288, 222–235.PubMedCrossRefGoogle Scholar
  201. Yerly, S., Kaiser, L., Race, E., Bru, J.P., Clavel, F. and Perrin, L., (1999), Transmission of antiretroviral-drug-resistant HIV-1 variants. Lancet, 354, 729–733.PubMedCrossRefGoogle Scholar
  202. Yerly, S., Vora, S., Rizzardi, P., Chave, J.P., Vernazza, P.L., Flepp, M., Telenti, A., Battegay, M., Veuthey, A.L., Bru, J.P., Rickenbach, M., Hirschel, B. and Perrin, L., (2001), Acute HIV infection: impact on the spread of HIV and transmission of drug resistance. AIDS, 15, 2287–2292.PubMedCrossRefGoogle Scholar
  203. Zaccarelli, M., Tozzi, V., Lorenzini, P., Trotta, M.P., Forbici, F., Visco-Comandini, U., Gori, C., Narciso, P., Perno, C.F. and Antinori, A., (2005), Multiple drug class-wide resistance associated with poorer survival after treatment failure in a cohort of HIV-infected patients. AIDS, 19, 1081–1089.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Jorge L. Martinez-Cajas
  • Marco Petrella
  • Mark A. Wainberg

There are no affiliations available

Personalised recommendations